4 months ago
2
Laurus Labs reported a crisp emergence successful consolidated nett net for the December quarter, with net jumping to ₹252 crore from the ₹92 crore a twelvemonth earlier, driven by a 26% year-on-year summation successful gross to ₹1,778 crore (₹1,415 crore).
Calling it different 4th of beardown operational and fiscal performance, Chief Financial Officer V.V. Ravi Kumar said maturation was led by a robust generics concern and sustained request successful CDMO small-molecule offerings. EBITDA margins stood astatine 27.3%, supported by continued operating leverage, portion gross margins improved to 60.9% from 56.9% successful the corresponding 4th of the erstwhile fiscal.
The generics concern recorded a 37% year-on-year summation successful the 3rd quarter, with revenues rising to ₹1,327 crore, driven chiefly by higher antiretroviral (ARV) volumes and beardown offtake successful prime molecules wrong developed markets. Revenue from the CDMO concern was level astatine ₹451 crore (₹448 crore) connected the backmost of 10% little gross successful the bio — ample molecules conception astatine ₹43 crore. The tiny molecules conception revenues roseate 2% to ₹408 crore.
Founder and CEO Satyanarayana Chava said “we are successfully executing connected our strategy with continued advancements successful important CDMO projects, ramping up caller launches and strengthened enactment successful antiretroviral successful driving beardown 4th and cumulative performance. These results corroborate our afloat twelvemonth outlook of beardown gross maturation and improving borderline momentum.”
